Business Context and Reporting Period
Company: Intensity Therapeutics, Inc. (INTS)
Filing Type: Form 10-Q (Unaudited)
Period: Three months ended March 31, 2025
Business Overview: A late-stage clinical biotechnology company developing INT230-6, an intratumoral cancer treatment using the DfuseRxSM platform. The company has no product revenue and relies on equity financing.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3.35) million | $(4.60) million |
| Loss Per Share (Basic/Diluted) | $(0.22) | $(0.34) |
| Cash and Cash Equivalents (End of Period) | $0.93 million | $7.46 million |
| Accumulated Deficit | $(70.13) million | $(55.12) million |
| Net Cash Used in Operating Activities | $(1.99) million | $(4.37) million |
| Total Assets | $3.07 million | $4.78 million |
| Total Liabilities | $2.73 million | $1.87 million |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by $1.35 million (28%) to $3.39 million.
- Research & Development (R&D): Decreased $0.63 million (22%) primarily due to lower stock-based compensation ($0.41 million reduction) and reduced contract manufacturing costs ($0.19 million reduction) as no new batches were manufactured in Q1 2025.
- General & Administrative (G&A): Decreased $0.72 million (37%) driven by lower stock-based compensation ($0.31 million), reduced insurance costs, and lower legal/audit fees.
- Cash Position: Cash and cash equivalents declined significantly from $2.59 million at year-end 2024 to $0.93 million at March 31, 2025, reflecting a net cash burn of $1.66 million for the quarter.
- Financing Activity: The company raised $0.33 million in net proceeds from an At-The-Market (ATM) offering during the quarter.
Outlook, Risks, and Unusual Items
- Liquidity and Going Concern: Management has expressed "substantial doubt" about the company's ability to continue as a going concern. Based on cash on hand plus proceeds from a subsequent April 2025 offering, the company projects sufficient funds only through the third quarter of 2025.
- Clinical Trial Pause: In March 2025, the company paused new site activations and patient enrollments for the Phase 3 INVINCIBLE-3 Study (Soft Tissue Sarcoma) due to funding constraints. Enrollment had reached 23 patients prior to the pause. The company prioritized funding for the Phase 2 INVINCIBLE-4 Study (Triple-Negative Breast Cancer).
- Subsequent Financing: In April 2025, the company completed a public offering raising $2.35 million gross ($1.9 million net) by selling common stock and warrants. This was necessary to extend the operating runway.
- Risk Factors: Risks include the inability to raise additional capital, potential delisting from Nasdaq, and the impact of military actions in Russia and Israel on patent protection.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.9 million net proceeds from the April 2025 offering to sustain operations through Q3 2025 and the timeline for the next required capital raise.
- Phase 3 Restart: Monitor announcements regarding the resumption of patient enrollment in the paused INVINCIBLE-3 Study and the impact of the pause on the study's timeline.
- Dilution Impact: Assess the dilution effect of the April 2025 offering (3.13 million shares plus warrants) and the remaining capacity under the ATM agreement.
- Liabilities: Review the increase in accrued expenses (from $0.51 million to $1.01 million) and accounts payable to understand outstanding vendor obligations.